Eric H. Rubin

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project

Fred R. Hirsch, Abigail McElhinny, Dave Stanforth et al. · Journal of Thoracic Oncology · 2016 · 1.2K citations · Full text

Cancer Immunosurveillance, Advanced Lung Disease, Medicine +8

Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I Trial

Roy S. Herbst, Anne‐Marie Maddox, Mace L. Rothenberg et al. · Journal of Clinical Oncology · 2002 · 577 citations

Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement

Edward S. Kim, Suanna S. Bruinooge, Samantha Roberts et al. · Journal of Clinical Oncology · 2017 · 448 citations

Eligibility Criteria, Clinical Endpoint, American Society +16

Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce

Harriet M. Kluger, Hussein A. Tawbi, Maria Libera Ascierto et al. · Journal for ImmunoTherapy of Cancer · 2020 · 260 citations · Full text

New Agents, Immunology, Immunoediting +17

Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells.

Shyamal D. Desai, Tsai‐Kun Li, Alexandra Rodriguez-Bauman et al. · PubMed · 2001 · 221 citations

Breast Oncology, Cell Death, Resistance Mechanism +19